SOURCE: Viral Genetics

March 21, 2007 10:00 ET

Viral Genetics Updates Scientific Milestones

AZUSA, CA -- (MARKET WIRE) -- March 21, 2007 -- In January of this year Viral Genetics (OTCBB: VRAL) announced that it had preliminarily identified two peptides as the active components of its HIV/AIDS drug candidate, VGV-1, and further stated its follow up plan to confirm the findings. This research is important because identification of the active components should allow the Company to pursue studies aimed at enhancing the antiviral results of VGV-1, which is a significant development in moving VGV-1 forward as a HIV/AIDS therapy. This enhancement or "optimization" process would be accomplished largely through identifying the components' mechanism of action and studying how different concentrations of the components influence the antiviral effects.

Since then, the Company has duplicated the findings using a third-party, independent lab and subsequently met with its Scientific Advisory Board for review of the data.

The advisory board recommended that, in order to ensure that no components were missed in the first, duplicated studies, the Company complete a brief series of tests using a different identification method. Following these tests, it was recommended that the Company initiate the next step of the development strategy which consists of various in vitro "activity studies" (aimed at revealing the mechanism of action and examining other potential uses of the compound).

Haig Keledjian, President of the Company, explained, "Our approach will be comprehensive ensuring that when we move past this phase of development, there will be no unanswered questions. We have nearly completed the studies recommended by the Scientific Advisory Board to isolate the active components. We intend to begin the more intriguing activity studies following that, as we continue to move closer to our goal of filing an IND with the FDA."

In recent studies, a reduction of HIV viral load was observed in a subset of patients after treatment with VGV-1 versus patients receiving placebo. As reported in the Company's poster presentation at the 2006 XVI International AIDS Conference, VGV-1 treated subjects also demonstrated apparent beneficial immunological changes when compared with placebo.

The World Health Organization estimates approximately 40 million people are now living with HIV. Even with the available treatments for AIDS, there is a substantial population in need of alternative therapies and hope remains that progress will be made in discovering new therapies that bolster patients' immune systems.

About VGV-1

VGV-1 is a therapy based on thymus nuclear protein which is extracted from bovine thymus tissue. As a type of immune-based therapy, it focuses on boosting the immune system to allow the body to fight HIV more efficiently. Thymus nuclear protein technology has been studied in five human clinical trials for the treatment of HIV infection and AIDS.

About Viral Genetics

Viral Genetics, Inc. is a biotechnology company that discovers and develops immune-based therapies for HIV and AIDS using its thymus nuclear protein compound. This compound may have other potential applications for other infectious, autoimmune, and immunological deficiency diseases that the company intends to study in the future. Viral Genetics believes that VGV-1 represents a significant and unique approach to treating HIV due to the apparently novel mechanism, low toxicity profile, simple dosing regimen, and short-course of treatment. Online at www.viralgenetics.com

This news release contains forward-looking statements that involve risks and uncertainties associated with financial projections, budgets, milestone timelines, clinical development, regulatory approvals, and other risks described by Viral Genetics, Inc. from time to time in its periodic reports filed with the SEC. VGV-1 is not approved by the US Food and Drug Administration or by any comparable regulatory agencies elsewhere in the world. While Viral Genetics believes that the forward-looking statements and underlying assumptions contained therein are reasonable, any of the assumptions could be inaccurate, including, but not limited to, the ability of Viral Genetics to establish the efficacy of VGV-1 in the treatment of any disease or health condition, the development of studies and strategies leading to commercialization of VGV-1 in the United States, the obtaining of funding required to carry out the development plan, the completion of studies and tests on time or at all, and the successful outcome of such studies or tests. Therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the forward-looking statements should not be regarded as a representation by Viral Genetics or any other person that the objectives and plans of Viral Genetics will be achieved.

Contact Information

  • For additional information, please contact:
    Viral Genetics
    626-334-5310